The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Edwards Lifesciences Corp

NYSE: EW
Last

(U.S.) $81.04

Today's change+2.00 +2.53%
Updated February 12 4:03 PM EST. Delayed by at least 15 minutes.
 

Edwards Lifesciences Corp

NYSE: EW
Last

(U.S.) $81.04

Today's change+2.00 +2.53%
Updated February 12 4:03 PM EST. Delayed by at least 15 minutes.

Edwards Lifesciences Corp up sharply

Edwards Lifesciences Corp closed up sharply Friday, rallying (U.S.)$2.00 or 2.53% to (U.S.)$81.04. Shares have lost 1.19% over the last five days, but are unchanged over the last year to date. This security has outperformed the S&P 500 by 33.18% during the last year.

Key company metrics

  • Open(U.S.) $79.61
  • Previous close(U.S.) $79.04
  • High(U.S.) $81.12
  • Low(U.S.) $78.60
  • Bid / Ask-- / --
  • YTD % change+2.61%
  • Volume2,186,628
  • Average volume (10-day)2,798,135
  • Average volume (1-month)2,290,661
  • Average volume (3-month)2,128,234
  • 52-week range(U.S.) $61.38 to (U.S.) $84.84
  • Beta0.60
  • Trailing P/E36.08×
  • P/E 1 year forward30.74×
  • Forward PEG2.04×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $2.25
Updated February 12 4:03 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+19.85%

Based on its net profit margin of 19.85%, Edwards Lifesciences Corp is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX2.43%Sector:HealthcareIndustry:Advanced Medical Equipment
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015
Revenue671616617590
Total other revenue--------
Total revenue671616617590
Gross profit495469458454
Total cost of revenue176147159136
Total operating expense504465475428
Selling / general / administrative222212214203
Research & development981019886
Depreciation / amortization--------
Interest expense (income), net operating--444
Unusual expense (income)3210
Other operating expenses, total2000
Operating income167151142163
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax167151142163
Income after tax141118113123
Income tax, total26333039
Net income141118113123
Total adjustments to net income--------
Net income before extra. items141118113123
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items141118113123
Inc. avail. to common incl. extra. items141118113123
Diluted net income141118113123
Dilution adjustment000--
Diluted weighted average shares221220220221
Diluted EPS excluding extraordinary itemsvalue per share0.640.540.510.56
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share0.650.550.520.56